Structure and functional studies of potassium channels in T-lymphocytes: targets for the design of immunosuppresive agents
Dr. Chandy's lab is developing therapeutic agents for human disease by targeting potassium channels. Dr. Chandy's main focus is on autoimmune diseases (multiple sclerosis, rheumatoid arthritis, type-1 diabetes mellitus, psoriasis), organ and bone marrow transplantation, atherosclerosis, vascular restenosis following angioplasty, and neurological diseases. His lab has cloned the relevant potassium channel genes, developed specific inhibitors of these channels, demonstrated the functional role of the channels in normal and diseased cells, and demonstrated therapeutic efficacy of our inhibitors in animal models of human disease. Pre-clinical toxicity studies are underway for the most promising compounds. Dr. Chandy's lab intends to evaluate these compounds in patients in the next few years with the hope that someday will ameliorate human disease.